<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9B855EFE-01C4-4EC2-9E29-A842C94C30C2"><gtr:id>9B855EFE-01C4-4EC2-9E29-A842C94C30C2</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Edward</gtr:otherNames><gtr:surname>Cheetham</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0700412"><gtr:id>98FBFC6A-0AAA-413C-BD12-4AC8F8EC259A</gtr:id><gtr:title>Molecular chaperone models and neurodegeneration</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700412</gtr:grantReference><gtr:abstractText>As we age nerve cells in the brain can start to malfunction and die leading to dementia and other diseases. This process is associated with clumps of aggregated proteins. Cells have molecular machines made of chaperone proteins that can stop protein aggregation. We are testing if a special nerve cell chaperone is involved in these processes in the brain and if we can manipulate this chaperone to affect the development or effects of the aggregates. This research could highlight this special chaperone as a potential new target for the development of treatments for several forms of dementia and neurodegeneration, such as Alzheimer?s, Parkinson?s, Huntington?s and Motor neuron disease.</gtr:abstractText><gtr:technicalSummary>Protein folding and quality control are facilitated by molecular chaperones and aberrant protein folding is associated with many forms of neurodegeneration. The neuronal proteins HSJ1a and HSJ1b are unique mammalian chaperones. They combine a J domain that regulates Hsp70, a novel substrate binding domain and two ubiquitin interacting motifs (UIMs). This combination of motifs enables HSJ1 proteins to sort misfolded proteins for proteasomal degradation. We have shown that HSJ1 proteins are neuroprotective against polyglutamine mediated neurodegeneration. HSJ1a suppressed polyglutamine aggregation dependent on correct subcellular targeting, a functional J domain and the UIMs, whereas HSJ1b did not affect polyglutamine aggregation but still enhanced neuronal survival associated with a stimulation of BDNF release. These data suggest that both HSJ1 proteins could be important modulators of neurodegeneration. With the support of an MRC Pathfinder we have generated transgenic lines which overexpress HSJ1a or HSJ1b and a conditional animal model which lacks both HSJ1 proteins. This proposal aims to study the effect of manipulating HSJ1 expression on neuronal development, function, stress tolerance and neurodegeneration. These HSJ1 transgenic mice will be crossed with a range of animal models of neurodegeneration to test if the overexpression of either isoform can protect against neurodegeneration or if the absence of HSJ1 exacerbates neurodegeneration in these models. We will also delineate the mechanisms of HSJ1 mediated neuroprotection and test if HSJ1 proteins are involved in the neuroprotective action of certain drugs. These studies will address an important question relating to the role of molecular chaperones in the nervous system and importantly they will also enhance our understanding of their role in neurodegeneration which could have potential therapeutic applications.</gtr:technicalSummary><gtr:fund><gtr:end>2010-08-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>465154</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine KCL</gtr:department><gtr:description>Htt collaboration</gtr:description><gtr:id>D865D372-DCD3-4D1F-A574-F86F2BDECF29</gtr:id><gtr:impact>Chaperone-mediated improvement in a mouse model of HD Sergey Novesolov, John Labbadia, John S. Bett, Gillian P. Bates and Michael E. Cheetham 20th Molecular Chaperone Club meeting, Dec 14-15, 2009, Warwick UK.
A manuscript describing the work in detail is currently in preparation</gtr:impact><gtr:partnerContribution>This collaboration has enabled the in depth analyses of the role of HSJ1 in a Huntington's disease model.</gtr:partnerContribution><gtr:piContribution>We have provided transgenic and biochemical resources and expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Leeds Institute of Molecular Medicine</gtr:department><gtr:description>Parkin collaboration</gtr:description><gtr:id>E3B9E27A-0D1E-4E4C-9970-C4CFE9B15E76</gtr:id><gtr:impact>Rose JM, Novoselov SS, Robinson PA, Cheetham ME. (2010) Molecular chaperone mediated rescue of a Parkin RING1 mutant. Hum Mol Genet. Oct 1. [Epub ahead of print] PMID: 20889486

Morrison, E, Thompson, J. Williamson, SJ, Cheetham, ME and Robinson, PA (2010) A simple cell based assay to measure Parkin activity J. Neurochem in press DOI: 10.1111/j.1471-4159.2010.07113.x</gtr:impact><gtr:partnerContribution>Provided reagents and advice to help us study the ability of chaperones to rescue mutant Parkin function</gtr:partnerContribution><gtr:piContribution>We tested the ability of chaperones to rescue mutant Parkin function and helped develop a cell based assay for Parkin function</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MNDA 19th International Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>C7E26650-0109-42E7-8953-CCC92C9CDF5A</gtr:id><gtr:impact>Our data on the role of chaperones in ALS was presented as a platform presentation to an international audience

The presentation was well received and initiated a collaboration</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>StakeHolder Liaison Group</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>E1CD0604-D5C4-4CD2-9C01-6383DC115F3F</gtr:id><gtr:impact>This is a group formed from the membership of the British Retinitis Pigmentosa Society to monitor our work on protein folding therapies for RP. Formed as part of BIG lottery funding in related project but the work arising from this MRC funding is also discussed.

The group meets 3 times a year and has been important for disseminating information to the Society through the web site and brochures.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BSCB/BSDB 2008 meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>AD1982AF-4E5D-47A1-B840-B1973D0D8F5C</gtr:id><gtr:impact>Our data on molecular chaperone manipulation of tau aggregation was presented as a platform presentation to an international audience.

The presentation was well received</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1158571</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>WellcomeTrust Programme Grant (Investigation and manipulation of photoreceptor proteostasis.)</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>092621</gtr:fundingRef><gtr:id>265F0EF3-79CF-4DFE-8867-CCD4EFFFC966</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>33000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCL Impact PhD Studentship</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>University College London (UCL)</gtr:fundingOrg><gtr:id>5E24A639-9352-4501-ABA0-6AE2A7739066</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>43000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MNDA Project Grant</gtr:description><gtr:end>2009-04-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:id>06B01A9D-C5FF-4033-8A8A-D3CCE70DC73D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>New transgenic mice with ablated or increased molecular chaperone expression</gtr:description><gtr:id>975DCDC4-D7D4-4C30-9A18-DE0387CDAB68</gtr:id><gtr:impact>These are valuable tools for probing the biology of molecular chaperones and their role in disease.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>HSJ1 transgenics</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have developed cell models for Alzheimer's Parkinson's, ALS, retinitis pigmentosa and Huntington's disease</gtr:description><gtr:id>4FD93FAA-7BF7-4869-B050-675F5580F311</gtr:id><gtr:impact>We have distributed and received reagents for these cell models that are advancing our understanding of neurodegenerative disease.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Cell models of neurodegeneration</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Transgenic mice with altered levels of chaperone proteins</gtr:description><gtr:id>C10587C9-6FC5-4ED4-8CE3-CEFBCAFC7B06</gtr:id><gtr:impact>These transgenic mice are proving important for our understanding of neurodegenerative disease</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Chaperone transgenics</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EA13AA96-5A6D-4390-BB06-6807CC1A80B0"><gtr:id>EA13AA96-5A6D-4390-BB06-6807CC1A80B0</gtr:id><gtr:title>Molecular chaperone mediated late-stage neuroprotection in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5afca19d2db41c572f0f172969c92bb2"><gtr:id>5afca19d2db41c572f0f172969c92bb2</gtr:id><gtr:otherNames>Novoselov SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/101B37BD-00DB-49B5-8F0E-1E2AE7176879"><gtr:id>101B37BD-00DB-49B5-8F0E-1E2AE7176879</gtr:id><gtr:title>Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/51fb847e6a36c4c4664cccb152cf38ba"><gtr:id>51fb847e6a36c4c4664cccb152cf38ba</gtr:id><gtr:otherNames>Kalmar B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/30E3A354-518F-4678-94C2-DE6EFE03B8EE"><gtr:id>30E3A354-518F-4678-94C2-DE6EFE03B8EE</gtr:id><gtr:title>A simple cell based assay to measure Parkin activity.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7558b63aa36387ed938f3baffbc24f36"><gtr:id>7558b63aa36387ed938f3baffbc24f36</gtr:id><gtr:otherNames>Morrison E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5EFE88F6-053A-4113-B343-744DF9FD3E2C"><gtr:id>5EFE88F6-053A-4113-B343-744DF9FD3E2C</gtr:id><gtr:title>Suppression of protein aggregation by chaperone modification of high molecular weight complexes.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/10cc748b43a0d6682acfc8aa07535c31"><gtr:id>10cc748b43a0d6682acfc8aa07535c31</gtr:id><gtr:otherNames>Labbadia J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/30081364-F209-4578-91A1-1B18EBDE20BC"><gtr:id>30081364-F209-4578-91A1-1B18EBDE20BC</gtr:id><gtr:title>Molecular chaperones and photoreceptor function.</gtr:title><gtr:parentPublicationTitle>Progress in retinal and eye research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eeab131b3d69e24baab007050733e072"><gtr:id>eeab131b3d69e24baab007050733e072</gtr:id><gtr:otherNames>Kosmaoglou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1350-9462</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2446B415-3212-451A-BC7F-3BFBDDFE2CCE"><gtr:id>2446B415-3212-451A-BC7F-3BFBDDFE2CCE</gtr:id><gtr:title>Molecular chaperones and neuronal proteostasis.</gtr:title><gtr:parentPublicationTitle>Seminars in cell &amp; developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f53b11de0d73641d654e1123e43facda"><gtr:id>f53b11de0d73641d654e1123e43facda</gtr:id><gtr:otherNames>Smith HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1084-9521</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/90AF5580-53D8-40EE-99AE-5B83F9E3DEA8"><gtr:id>90AF5580-53D8-40EE-99AE-5B83F9E3DEA8</gtr:id><gtr:title>Homocysteine-induced endoplasmic reticulum protein (herp) is up-regulated in parkinsonian substantia nigra and present in the core of Lewy bodies.</gtr:title><gtr:parentPublicationTitle>Clinical neuropathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8a6d5e6aa976fdb1e1d38c68cb050a76"><gtr:id>8a6d5e6aa976fdb1e1d38c68cb050a76</gtr:id><gtr:otherNames>Slodzinski H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0722-5091</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0E60A016-6807-481A-9905-6896FE44620B"><gtr:id>0E60A016-6807-481A-9905-6896FE44620B</gtr:id><gtr:title>DnaJB6 is present in the core of Lewy bodies and is highly up-regulated in parkinsonian astrocytes.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8958c09e49ef3fc800fb067584f5420e"><gtr:id>8958c09e49ef3fc800fb067584f5420e</gtr:id><gtr:otherNames>Durrenberger PF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0360-4012</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8A1EE6C1-BA9A-43DA-862B-FDF87837AF59"><gtr:id>8A1EE6C1-BA9A-43DA-862B-FDF87837AF59</gtr:id><gtr:title>Molecular chaperone-mediated rescue of mitophagy by a Parkin RING1 domain mutant.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/22ea6f41ebff3ca3ff06c86954855e1e"><gtr:id>22ea6f41ebff3ca3ff06c86954855e1e</gtr:id><gtr:otherNames>Rose JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700412</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>